Recall Register

Drug recall: Estradiol Transdermal System, USP (Twice-Weekly) 0.0375mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited…

Class III FDA enforcement event 94649. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Failed Impurities/Degradation Specifications.

Class III, in the words of FDA

a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences

Zydus Pharmaceuticals (USA) Inc started this drug recall on 16 May 2024. The firm address in the FDA record is in Pennington, NJ. FDA put the recall in Class III. FDA event 94649 has 2 product records. The first FDA enforcement report date is 12 Jun 2024. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide within the United States

Recalling firm

Zydus Pharmaceuticals (USA) Inc, Pennington, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

2 product records in the event.

FDA event 94649: product records
Recall numberProductQuantityClassStatusReport date
D-0542-2024Estradiol Transdermal System, USP (Twice-Weekly) 0.0375mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1192-821,360 unitsClass IIIOngoing12 Jun 2024
D-0543-2024Estradiol Transdermal System, USP (Twice-Weekly) 0.025mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1191-813,440 unitsClass IIIOngoing12 Jun 2024

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class III: The lowest of the three FDA recall classes.

The event in context

Drug events that started in 2024
319
Share of these events in Class III
15%
Product records in this event
2Median of the firm: 1
Events of the firm on the register
54

Other events of the firm

Other FDA enforcement events of Zydus Pharmaceuticals (USA) Inc
InitiatedProduct (first record)TypeClassRecords
5 Aug 2026Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, DrugClass II1
29 Apr 2026Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, DrugClass II2
9 Mar 2026Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., IndiaDrugClass II1
30 Dec 2025Icosapent Ethyl capsules, 1 gram, 120-count bottles, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India, DistDrugClass II1
19 Dec 2025traZODONE Hydrochloride Tablets, USP, 100mg, 1,000 Tablets, Rx only, Manufactured by: Zydus Lifesciences Ltd., India, DiDrugClass III1
23 Oct 2025Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., ADrugClass II1
22 Oct 2025clomiPRAMINE Hydrochloride, Capsules, USP, 25 mg, packaged in a) 30-count bottles (NDC 16714-849-01), b) 90-count bottleDrugClass II3
24 Sep 2025Entecavir Tablets, USP, 0.5 mg, 30-count bottle, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, DiDrugClass II2
4 Sep 2025Entecavir Tablets, USP, 0.5 mg, 30 Tablets, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, DistribDrugClass II2
3 Sep 2025Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 100-count bottle, Rx only, Manufactured By: Zydus Lifesciences Ltd., BDrugClass II10

Zydus Pharmaceuticals (USA) Inc: all 54 events

Official channels

Cite this page

Recall Register. FDA enforcement event 94649. https://recallregister.com/fda/iii/94649/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide within the United States
What quantity of product is in FDA event 94649?
The event has 2 product records. The first record gives this quantity: 21,360 units
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2024 have the same class?
15% of the 319 drug events that started in 2024 are in Class III.